{"id":"W2168391786","doi":"10.2174/092986706779026174","title":"Targeting the EGFR Pathway for Cancer Therapy","year":2006,"lang":"en","type":"review","venue":"Current Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Strong; CancerCare Manitoba Foundation; Manitoba Medical Service Foundation; Manitoba Health Research Council","keywords":"Cetuximab; Medicine; Gefitinib; Panitumumab; Pertuzumab; Lapatinib; Erlotinib; Amphiregulin; Epidermal growth factor receptor; Lung cancer; Targeted therapy; Trastuzumab; Cancer; Cancer research; Breast cancer; Epidermal growth factor; Oncology; Internal medicine; Colorectal cancer; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001003727,0.0006634517,0.001852135,0.00006123738,0.0002013129,0.00003875947,0.0006716913,0.0004105589,0.0008654483],"category_scores_gemma":[0.0004167707,0.0003742253,0.0007652137,0.0003948779,0.0003347525,0.00002356801,0.00009991771,0.001961304,0.00002742609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008143182,"about_ca_system_score_gemma":0.003150394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004716673,"about_ca_topic_score_gemma":0.00000147453,"domain_scores_codex":[0.9963025,0.00008464606,0.0009109873,0.0007666837,0.0010882,0.000846987],"domain_scores_gemma":[0.9976383,0.0005308299,0.0004345174,0.0007727547,0.0003083136,0.0003153275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003019151,0.00008843413,0.0000149389,0.06396613,0.0001283746,0.00001613766,0.00003219359,2.438215e-7,0.0000688583,0.00000333561,0.09916617,0.836485],"study_design_scores_gemma":[0.000806595,0.00006513437,0.000001055459,0.03248009,0.0005280871,0.00006835352,0.00003056768,0.00001607466,0.0003160703,0.00001429694,0.9653414,0.0003322092],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001128751,0.9936523,0.00006497968,0.0005339817,0.00121042,0.002324914,0.000256893,0.00007958992,0.001865619],"genre_scores_gemma":[0.00001031201,0.983138,0.00003417711,0.00009238454,0.009994989,0.002740092,0.001038362,0.0001463339,0.002805366],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8661753,"threshold_uncertainty_score":0.999871,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1949928734727937,"score_gpt":0.4903576461793562,"score_spread":0.2953647727065626,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}